< LEADERBOARD/s/quercetinBotanicals

Quercetin

Also sold as: Quercetin aglycone · Isoquercitrin · Quercetin phytosome · EMIQ

Quercetin is a dietary flavonol marketed for allergy, inflammation and performance. Its most consistent clinical signal is a small reduction in blood pressure, with major limits on claims about glucose, immunity and enhanced-absorption products.

Energy

COMMUNITY_STACK_RATINGlive · n=0

Community

Not enough ratings yet: 0 of 10

Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.

+ Rate your experience (30 sec, anonymous)

NERD_PROTOCOL // EVIDENCE_MATRIXper goal

Research

EnergyLimited · benefit

Energy: Endurance meta-analyses report a trivial-to-small effect (ES 0.15, about 2%); this is not a meaningful general energy guarantee.

REALITY CHECK // Enhanced absorption is measurable for some formulations, but evidence that it improves hard clinical outcomes is missing. The antihistamine story contains class-level and preliminary data, not proof that quercetin treats MCAS. Overall inflammatory and glucose results are largely null.

Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.

Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.

CHECK_YOUR_BOTTLE.EXEruns in your browser · nothing is sent or stored

Check your bottle

Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.

Enter the amount from your label to see the result.

How it was studied

01 // STUDIED_DOSE_RANGE

Form and population matter

Blood-pressure studies commonly used at least 500 mg/day for more than eight weeks. Exercise trials had a median around 1000 mg/day and 11 days; a preliminary CPPS trial used 500 mg twice daily. Form-specific trial mass cannot be scaled by an absorption multiplier.

02 // TIMING_&_MATRIX

Administration context

Choose a declared form and matrix. Neither bromelain nor vitamin C has convincing human evidence for a quercetin absorption boost; formulation exposure cannot be translated directly into dose equivalence.

03 // EVALUATION_WINDOW

Match the studied window

Blood pressure is a chronic endpoint, usually weeks rather than hours. Exercise effects are small even in short studies; allergy and CPPS contexts are separate.

04 // SAFETY_&_QUALITY_GATE

Review limits and medicines

No official EFSA/NIH UL is established in the dossier. Oral doses up to about 1000 mg/day were generally tolerated short term in reviewed studies; this is not a lifelong safety ceiling or proof for high-exposure formulations. Pregnancy, lactation and pediatric supplemental-dose safety are insufficiently studied. Review medicines involving CYP3A4/P-gp, anticoagulants, thyroid disease and perioperative use. Nausea, abdominal discomfort and headaches may occur; historic IV nephrotoxicity is a different route.

UPPER LIMIT // No official EFSA/NIH UL is established in the dossier. Oral doses up to about 1000 mg/day were generally tolerated short term in reviewed studies; this is not a lifelong safety ceiling or proof for high-exposure formulations.

NERD'S NOTENerd Protocols · a clinical and sports dietitian based in the EU

Summary

Blood-pressure effects are small: pooled systolic reductions around 2-3 mmHg, with inconsistent diastolic results. Glucose and HOMA-IR benefits are not established. Allergy, respiratory and COVID findings require careful distinction between quercetin and whole flavonoid classes.

Mechanism

Quercetin influences redox, inflammatory and mast-cell pathways in experimental systems. Absorption depends strongly on glycosylation and delivery matrix; greater exposure does not automatically mean superior clinical outcomes.

Typical studied dose

Upper limit

POPULAR_STACKScombos with n ≥ 5

Popular stacks with Quercetin

Not enough stack data yet. A combination with Quercetin appears here once 5 people rate the same set.

> Rate my stack

Forms and label traps

Forms compared
Form on label	Active content	Studied range / day	Absorption & GI tolerance	Verdict
Quercetin aglycone, anhydrous or dihydrate Best for: Interpreting conventional trial doses.	Extract weight · marker not quantified	500–1000 mg	Low oral exposure; reference formulation. Nausea and GI discomfort can occur.	Studied standard [FORM // REFERENCE] Compare labelled full quercetin mass. Do not treat poor absorption as a conversion percentage. PMID 40037045
Quercetin-3-O-glucoside / isoquercitrin Best for: A declared glycoside formulation.	Unstandardized: active content unknown	no comparable trial range	Glycosylation can increase exposure in human studies. Usually well tolerated in studied settings.	Good option [FORM // CHECK_BASIS] No validated aglycone-equivalent clinical dose conversion. A comparable outcome interval is unavailable. PMID 40037045 PMID 20638359
Quercetin phytosome / lecithin complex Best for: Formulation-specific exposure evidence.	Unstandardized: active content unknown	no comparable trial range	Human absorption studies show higher exposure than aglycone; source reports about 20-fold in a form synthesis. Generally tolerated in available studies.	Good option [FORM // CHECK_BASIS] Use the declared complex and quercetin content separately; unknown marker fraction is 0 here, not 100%. No universal clinical target for total lecithin complex mass. PMID 40037045 PMID 30328058
Enzymatically modified isoquercitrin Best for: Specific EMIQ research, not generic equivalence.	Unstandardized: active content unknown	no comparable trial range	Higher absorption; an endothelial-function trial exists in at-risk volunteers. Generally tolerated in studied settings.	Good option [FORM // CHECK_BASIS] No source-supported common dose interval or marker percentage is supplied. Do not multiply standard efficacy by absorption. PMID 31870463 PMID 24680690

Common label traps

TRAP_01 // Quercetin lowers glucose and treats diabetes
Meta-analyses do not show consistent fasting-glucose or HOMA-IR improvement. A small insulin change is insufficient to establish diabetes treatment.
TRAP_02 // Bromelain makes it absorb dramatically better
The dossier contains no strong human evidence for that claim. A combination label is not an absorption trial.
TRAP_03 // Natural antihistamine cures allergy or MCAS
The allergy evidence includes polyphenol-class studies and incomplete quercetin citation records; it does not establish a cure or MCAS therapy.
TRAP_04 // More bioavailable means proportionally more effective
Exposure differences are not head-to-head proof of better symptoms, long-term outcomes or equal safety.

Other outcomes studied

Outside the five leaderboard goals. Same evidence levels as above.

BLOOD PRESSURE Moderate · benefit
Meta-analysis: SBP -3.04 mmHg (95% CI -5.75 to -0.33), DBP -2.63 mmHg; umbrella synthesis found SBP -1.9 mmHg and no DBP effect. Certainty ranges very low to moderate; stronger signals in metabolic syndrome.
PMID 27405810 PMID 37654199 PMID 31092175
ALLERGIC RHINITIS Limited · benefit
The dossier describes a 13-RCT, 823-person polyphenol-class synthesis and preliminary quercetin trials. These are not quercetin-only effect estimates; allergy titles are missing in the catalog and need review.
INFLAMMATORY MARKERS Limited · no benefit
No overall CRP, IL-6 or TNF-alpha effect in the cited synthesis; disease, sex and dose subgroups show signals. Universal anti-inflammatory claims overstate the evidence.
PMID 31213101 PMID 31017459 PMID 37654199
COVID-19 Limited · benefit
Six small trials produced an ICU-admission OR 0.31 (95% CI 0.10-0.99), with wide uncertainty. This preliminary disease-specific finding does not establish general immunity or current standard treatment.
PMID 36779438
RESPIRATORY INFECTIONS Limited · benefit
Flavonoid-class reviews suggest fewer URTIs; their combined effects cannot be assigned to isolated quercetin.
PMID 27184276 PMID 33858268
CHRONIC PELVIC PAIN / CPPS Limited · benefit
One old preliminary trial of 500 mg twice daily suggested symptom benefit in men with category III prostatitis, not an anxiety intervention.
PMID 10604689
GLUCOSE CONTROL Moderate · no benefit
RCT syntheses report no consistent fasting-glucose or HOMA-IR improvement; a small insulin change does not establish treatment efficacy.
PMID 31940027 PMID 37654199
URIC ACID / GOUT No established evidence
A narrative review and mechanisms do not establish an isolated-quercetin gout treatment benefit. This is unestablished, not a negative dedicated clinical meta-analysis.
PMID 35903522

Reader questions

Which form actually absorbs better?

Human formulation studies support exposure differences for glycosides and phytosomes. They do not establish a proportional symptom benefit or a validated lower equivalent dose.

Can I use it for histamine symptoms or MCAS?

Allergic-rhinitis findings are preliminary and partly class-level. MCAS diagnosis and treatment need clinical assessment; do not replace indicated care with this dossier signal.

Is daily use for years established safe?

No. Most oral safety data are short term. Review medicine interactions and persistent GI symptoms rather than interpreting the lack of a UL as unlimited safety.

Stack interactions

Caution Cyclosporine and narrow-therapeutic-index CYP3A4/P-gp medicines [CAUTION // REVIEW_CONTEXT]
Rat and in-vitro findings show transporter/enzyme effects; direction is not reliably predictable from one model. Review with a pharmacist rather than guessing a spacing interval.
PMID 21466223 PMID 27510982 PMID 16442130
Caution Anticoagulants, antiplatelets and surgery [CAUTION // REVIEW_CONTEXT]
Antiplatelet/antithrombotic signals in animal and mechanistic studies create a potential bleeding concern; human clinical risk magnitude is not established.
PMID 39127114 PMID 41380488
Caution Thyroid disease / levothyroxine [CAUTION // REVIEW_CONTEXT]
Thyroid-peroxidase inhibition is an in-vitro finding, not proof of clinical hypothyroidism. Discuss supplemental use in existing thyroid disease.
PMID 8924586
Caution Vitamin C, bromelain and luteolin [CAUTION // REVIEW_CONTEXT]
Recycling and mast-cell synergy are mechanistic suggestions; improved human absorption or MCAS outcomes from these stacks are not established.

Red flags: interactions and who should avoid it

Interactions

Cyclosporine and narrow-therapeutic-index CYP3A4/P-gp medicines: Rat and in-vitro findings show transporter/enzyme effects; direction is not reliably predictable from one model. Review with a pharmacist rather than guessing a spacing interval. Anticoagulants, antiplatelets and surgery: Antiplatelet/antithrombotic signals in animal and mechanistic studies create a potential bleeding concern; human clinical risk magnitude is not established. Thyroid disease / levothyroxine: Thyroid-peroxidase inhibition is an in-vitro finding, not proof of clinical hypothyroidism. Discuss supplemental use in existing thyroid disease. Vitamin C, bromelain and luteolin: Recycling and mast-cell synergy are mechanistic suggestions; improved human absorption or MCAS outcomes from these stacks are not established.

Avoid or ask a doctor first if

Pregnancy, lactation and pediatric supplemental-dose safety are insufficiently studied. Review medicines involving CYP3A4/P-gp, anticoagulants, thyroid disease and perioperative use. Nausea, abdominal discomfort and headaches may occur; historic IV nephrotoxicity is a different route.

Sources (PubMed, 25)

Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PMID 27405810 · 2016 · systematic review / meta-analysis
Pooled small blood-pressure reductions.
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials.
PMID 37654199 · 2023 · systematic review / meta-analysis
Umbrella synthesis and inconsistent diastolic/glucose/inflammatory results.
The Effects of Quercetin Supplementation on Blood Pressures and Endothelial Function Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
PMID 31092175 · 2019 · systematic review / meta-analysis
Metabolic-syndrome subgroup blood-pressure context.
Quercetin and endurance exercise capacity: a systematic review and meta-analysis.
PMID 21606866 · 2011 · systematic review / meta-analysis
Trivial-to-small endurance effect, ES 0.15.
Effects of quercetin supplementation on endurance performance and maximal oxygen consumption: a meta-analysis.
PMID 22805526 · 2013 · systematic review / meta-analysis
Small endurance/VO2max synthesis.
Impact of quercetin on systemic levels of inflammation: a meta-analysis of randomised controlled human trials.
PMID 31213101 · 2020 · systematic review / meta-analysis
Overall null inflammatory effects with subgroup signals.
The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials.
PMID 31017459 · 2020 · systematic review / meta-analysis
Metabolic-syndrome lipid/inflammatory synthesis.
Quercetin for the treatment of COVID-19 patients: A systematic review and meta-analysis.
PMID 36779438 · 2023 · systematic review / meta-analysis
Preliminary COVID clinical signal from small trials.
Effect of Flavonoids on Upper Respiratory Tract Infections and Immune Function: A Systematic Review and Meta-Analysis.
PMID 27184276 · 2016 · systematic review / meta-analysis
Flavonoid-class URTI effects, not quercetin-only efficacy.
Effects of select dietary supplements on the prevention and treatment of viral respiratory tract infections: a systematic review of randomized controlled trials.
PMID 33858268 · 2021 · systematic review / meta-analysis
Broader supplement review of respiratory infections.
Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial.
PMID 10604689 · 1999 · randomized controlled trial
Preliminary category III prostatitis trial.
Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: a systematic review and meta-analysis.
PMID 31940027 · 2020 · systematic review / meta-analysis
No consistent glucose improvement.
A review on benefits of quercetin in hyperuricemia and gouty arthritis.
PMID 35903522 · 2022 · narrative review
Uric-acid mechanisms and limited clinical context.
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies.
PMID 40037045 · 2025 · systematic review / meta-analysis
Human formulation bioavailability differences.
Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin.
PMID 30328058 · 2019 · randomized controlled trial
Phytosome absorption study.
alpha-Oligoglucosylation of a sugar moiety enhances the bioavailability of quercetin glucosides in humans.
PMID 20638359 · 2010 · randomized controlled trial
Human glycosylation-related bioavailability.
Enzymatically modified isoquercitrin improves endothelial function in volunteers at risk of cardiovascular disease.
PMID 31870463 · 2020 · randomized controlled trial
EMIQ endothelial-function study in at-risk volunteers.
Isoquercitrin: pharmacology, toxicology, and metabolism.
PMID 24680690 · 2014 · narrative review
Isoquercitrin pharmacology and toxicology.
Safety Aspects of the Use of Quercetin as a Dietary Supplement.
PMID 29127724 · 2018 · narrative review
Oral safety and long-term evidence limits.
Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4.
PMID 21466223 · 2011 · animal / mechanistic study
Animal cyclosporine interaction, not a predictable human effect.
Impact of quercetin‑induced changes in drug‑metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats.
PMID 27510982 · 2016 · animal / mechanistic study
Rat transporter/enzyme interaction findings.
MDR- and CYP3A4-mediated drug-herbal interactions.
PMID 16442130 · 2006 · narrative review
MDR/CYP3A4 interaction review.
Studies on in vivo antithrombotic activity of quercetin, a natural flavonoid isolated from a traditional medicinal plant, African eggplant (Solanum indicum).
PMID 39127114 · 2024 · animal / mechanistic study
Animal antithrombotic activity.
Quercetin targeted NF-κB to regulate platelet activation and prevent arterial thrombosis.
PMID 41380488 · 2026 · animal / mechanistic study
Mechanistic/animal platelet-activation findings.
Inhibition of thyroid peroxidase by dietary flavonoids.
PMID 8924586 · 1996 · in vitro study
In-vitro thyroid-peroxidase inhibition.

Community comments

No approved comments yet. Comments are held for moderation.

+ Rate this